FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill

Merck announced the FDA's acceptance of its New Drug Application for doravirine/islatravir (DOR/ISL), a once-daily, oral, two-drug, single-tablet regimen for virologically suppressed adults with HIV-1. This investigational therapy is notable as it represents the first non-integrase inhibitor-based two-drug regimen to demonstrate comparable efficacy and safety to the current three-drug standard in pivotal Phase III studies, with an FDA decision anticipated by April 28, 2026. Despite this significant pipeline development, Merck's shares have underperformed, declining 15.5% year-to-date against an industry rise of 0.2%.

Analysis

Merck has achieved a key regulatory milestone with the FDA's acceptance of its New Drug Application for the HIV-1 treatment doravirine/islatravir (DOR/ISL), setting a target decision date of April 28, 2026. This development positions DOR/ISL as a significant long-term pipeline asset, notable for being the first potential non-integrase inhibitor-based two-drug regimen to demonstrate non-inferiority to the current three-drug standard in Phase III trials. However, this positive clinical news is sharply contrasted by the company's market performance, with Merck's stock having declined 15.5% year-to-date against a modest 0.2% rise for its industry. The company's broader HIV strategy involves further studies of islatravir and a critical collaboration with Gilead Sciences, a dominant force in the HIV market with its Biktarvy regimen and recently approved PrEP drug, highlighting a complex landscape of both competition and partnership.

Key Decisions for Investors

• Given the 2026 target decision date, view the DOR/ISL pipeline development as a long-term catalyst that is unlikely to impact near-term stock performance.
• The significant 15.5% year-to-date stock underperformance, despite positive regulatory news, warrants analysis to determine if this presents a value opportunity or reflects broader concerns not captured in this specific announcement.
• Closely monitor the competitive HIV landscape and Merck's collaboration with Gilead, as the commercial success of DOR/ISL will depend on its differentiation against established treatments like Biktarvy.